White Paper AGA: Gastroparesis: Clinical and Regulatory Insights for Clinical Trials

Pankaj J. Pasricha, Michael Camilleri, William L. Hasler, Henry P. Parkman

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Gastroparesis continues to represent a large unmet clinical need and a major opportunity for new drug development. This has led to increasing interest by federal funding agencies, regulatory bodies, and industry. This article summarizes the proceedings of the gastroparesis section of the “Drug Development Conference: Clinical Endpoints in Upper GI Disorders” organized by the American Gastroenterological Association in Washington, DC, on October 27–28, 2016. The presentation, diagnosis, and current therapeutic strategies are briefly reviewed, followed by a detailed discussion of the regulatory strategy, recommended endpoints, and future directions.

Original languageEnglish (US)
Pages (from-to)1184-1190
Number of pages7
JournalClinical Gastroenterology and Hepatology
Issue number8
StatePublished - Aug 2017


  • Clinical Trial Design
  • Endpoints
  • Gastroparesis

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'White Paper AGA: Gastroparesis: Clinical and Regulatory Insights for Clinical Trials'. Together they form a unique fingerprint.

Cite this